S R Penzak1, S K Chuck, G V Stajich. 1. Department of Pharmacy Practice, Mercer University, Southern School of Pharmacy, Atlanta, Georgia 30341-4155, USA.
Abstract
STUDY OBJECTIVE: To assess the efficacy and safety of HMG-CoA reductase inhibitors (statins) in patients with human immunodeficiency virus (HIV) infection and hyperlipidemia. DESIGN: Retrospective analysis. SETTING: HIV clinic. PATIENTS: Twenty-six HIV-infected patients with hyperlipidemia. INTERVENTION: Five patients received pravastatin, 13 lovastatin, 10 simvastatin, and 2 atorvastatin (total 30 courses). MEASUREMENTS AND MAIN RESULTS: Reductions in cholesterol and triglycetides were used to assess efficacy; creatine kinase (CK), liver enzymes, and myalgia were markers of statin toxicity. After a median of 8.2 and 7.2 months of treatment, the agents collectively reduced median baseline total cholesterol 27% (354 to 263 mg/dl) and triglycerides 15% (513 to 438 mg/dl), respectively. Two patients, one with marked CK elevations, experienced myalgias with lovastatin, and two experienced transaminase elevations 3 or more times the upper limit of normal. CONCLUSION: Statins are effective in reducing total cholesterol and triglycerides in HIV-infected patients, although lipid levels infrequently return to normal. Lovastatin should be avoided in patients receiving concomitant drugs that may potentiate skeletal muscle toxicity with this agent.
STUDY OBJECTIVE: To assess the efficacy and safety of HMG-CoA reductase inhibitors (statins) in patients with human immunodeficiency virus (HIV) infection and hyperlipidemia. DESIGN: Retrospective analysis. SETTING:HIV clinic. PATIENTS: Twenty-six HIV-infectedpatients with hyperlipidemia. INTERVENTION: Five patients received pravastatin, 13 lovastatin, 10 simvastatin, and 2 atorvastatin (total 30 courses). MEASUREMENTS AND MAIN RESULTS: Reductions in cholesterol and triglycetides were used to assess efficacy; creatine kinase (CK), liver enzymes, and myalgia were markers of statin toxicity. After a median of 8.2 and 7.2 months of treatment, the agents collectively reduced median baseline total cholesterol 27% (354 to 263 mg/dl) and triglycerides 15% (513 to 438 mg/dl), respectively. Two patients, one with marked CK elevations, experienced myalgias with lovastatin, and two experienced transaminase elevations 3 or more times the upper limit of normal. CONCLUSION: Statins are effective in reducing total cholesterol and triglycerides in HIV-infectedpatients, although lipid levels infrequently return to normal. Lovastatin should be avoided in patients receiving concomitant drugs that may potentiate skeletal muscle toxicity with this agent.
Authors: Sudershan Singh; James H Willig; Michael J Mugavero; Paul K Crane; Robert D Harrington; Robert H Knopp; Bradley W Kosel; Michael S Saag; Mari M Kitahata; Heidi M Crane Journal: Clin Infect Dis Date: 2010-12-28 Impact factor: 9.079
Authors: Yiannis S Chatzizisis; Konstantinos C Koskinas; Gesthimani Misirli; Christos Vaklavas; Apostolos Hatzitolios; George D Giannoglou Journal: Drug Saf Date: 2010-03-01 Impact factor: 5.606
Authors: Jonathan V Todd; Stephen R Cole; David A Wohl; Ross J Simpson; Michele Jonsson Funk; M Alan Brookhart; Jennifer Cocohoba; Daniel Merenstein; Anjali Sharma; Jason Lazar; Joel Milam; Mardge Cohen; Stephen Gange; Tené T Lewis; Greer Burkholder; Adaora A Adimora Journal: AIDS Patient Care STDS Date: 2017-11 Impact factor: 5.078